Earlier this week, FDA Commissioner Scott Gottlieb said that the agency will be diverting funds from pre-market drug reviews to post-market safety surveillance.
Earlier this week, FDA Commissioner Scott Gottlieb said that the agency will be diverting funds from pre-market drug reviews to post-market safety surveillance.